2024 Summit on Hematological Cancers

Nashville, TN US
October 11, 2024 to October 13, 2024

This CME-accredited activity 2024 Annual Summit on Hematologic Cancers features leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myeloproliferative neoplasms, multiple myeloma, and lymphoma. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances along with case-based discussion in the field of hematologic malignancies. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care.

Target Audience

  • Cancer care professionals
  • Practicing medical oncologists/hematologists
  • Radiation oncologists
  • Pathologists
  • Medical oncology and hematology fellows
  • Oncology nurses
  • Nurse practitioners
  • Physician assistants
  • Pharmacists

ORGANIZING COMMITTEE 

Course Director:

Binay Shah, MD, MHA Binaytara Foundation

Co-Chairs:

Nitin Jain, MD - MD Anderson Cancer Center

Navneet Majhail, MD, MS - Sarah Cannon

Sonali Smith, MD - University of Chicago

Shaji Kumar, MD - Mayo Clinic

Abstract Committee Chair:

Alexey Danilov, MD, PhD - City of Hope

Abstract Committee:

Hetty Carraway, MD - Cleveland Clinic

Nitin Jain, MD - MD Anderson Cancer Center

Jack Khouri, MD, FACP - Cleveland Clinic

Jayastu Senapati, MD - MD Anderson Cancer Center

Abhay Singh, MD, MPH - Cleveland Clinic

Hotel Information 

Booking link coming soon...

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review strategies for initial therapy and therapies for relapsed disease for patients with various hematologic malignancies
  • Outline efficacy and toxicities of small molecule inhibitors, monoclonal antibodies, antibody drug conjugates, T-cell redirecting bispecific antibodies, and CAR-T for the treatment of patients with hematologic malignancies
  • Apply an individualized treatment plan for patients with ALL, AML, CML, MPN, MM, NHL, HL, based on patient- and disease-related factors 
  • Review evolving role of autologous and allogeneic stem cell transplantation in different hematologic malignancies

GLOBAL ONCOLOGY PROJECT

Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/

Course summary
Available credit: 
  • 13.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 13.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 13.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 13.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 13.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 13.50 Contact Hours.
Course opens: 
11/22/2023
Course expires: 
12/31/2024
Event starts: 
10/11/2024 - 4:00pm PDT
Event ends: 
10/13/2024 - 12:00pm PDT
Cost:
$450.00

DAY 1 – Friday, October 11, 2024

All times are listed in Central Daylight Time (CDT)

12:00 PM – 01:00 PM  Registration, Exhibits, & Socialize


01:00 PM – 01:15 PM  Opening Remarks

01:15 PM – 01:30 PM  Addressing Global Cancer Health Disparities - Building a 200-Bed Cancer Hospital In Nepal - Justin Marquart


01:30 PM – 03:00 PM  Session 1 - ALL

Session Chair: Veronika Bachanova, MD, PhD

01:30 PM – 01:45 PM  What have we learned from pediatric regimens in ALL? - Haydar Frangoul, MD, MS

01:45 PM – 02:00 PM  CAR-T vs. Bispecifics Vs. Monoclonals in B-ALL - Marlise Luskin, MD, MSCE

02:00 PM – 02:15 PM  Treatment of Ph+/Ph-like ALL - Veronika Bachanova, MD, PhD

02:15 PM – 03:00 PM  Q & A and Case-Based Panel Discussion


03:00 PM – 03:30 PM  Break & Exhibits


03:30 PM – 05:00 PM  Session 2 - Aggressive Lymphomas

Session Chair: Sairah Ahmed, MD

03:30 PM – 03:45 PM  Updates in CAR-T therapy for aggressive lymphomas - Bhagirathbhai Dholaria, MD, MBBS

03:45 PM – 04:00 PM  Focus on elderly patients with aggressive B-cell lymphomas - Sairah Ahmed, MD

04:00 PM – 04:15 PM  Outpatient management of CAR-T therapy recipients - Jeremy Pantin, MD, FACP

04:15 PM – 05:00 PM  Q & A and Case-Based Discussion


DAY 2 – Saturday, October 12, 2024

07:00 AM – 08:00 AM  Registration, Exhibits & Socialize


08:30 AM – 10:00 AM  Session 3 - Multiple Myeloma - Newly Dx

Session Chairs: Shaji Kumar, MD & Nisha Joseph, MD

08:30 AM – 08:45 AM  Triplets or quadruplets – what is the right approach for newly diagnosed MM? - Nisha Joseph, MD

08:45 AM – 09:00 AM  Transplant for MM – does it still have a role? - Natalie Callander, MD

09:00 AM – 09:15 AM  Maintenance approaches for MM – one, two, or more drugs? - Prashant Kapoor, MD

09:15 AM – 10:00 AM  Q & A and Case-Based Discussion - Shuang Fu, MD, PhD; Jesus Berdeja, MD


10:00 AM – 10:45 AM  Break & Exhibits


10:45 AM – 12:15 PM  Session 4 - AML/MDS

Session Chair: Stephen Strickland, MD, MSCI

10:45 AM – 11:00 AM  Frontline Therapy of AML in 2024 

11:00 AM – 11:15 AM  Treatment options for relapsed/refractory AML Triplets in AML. Where are we and what’s next? - Naval Daver, MD

11:15 AM – 11:30 AM  Venetoclax in AML/ALL. Which subsets and why? - Marina Konopleva, MD, PhD

11:30 AM – 11:45 AM  Management of MDS after HMAs - Hetty Carraway, MD

11:45 AM – 12:15 PM  Q & A and Case-Based Discussion - Somedeb Ball, MD, MBBS


12:15 PM – 01:15 PM  Lunch, Exhibits, & Industry Sponsored Symposia


01:15 PM – 01:45 PM  (Keynote) 


 01:45 PM – 03:15 PM  Session 5 - CLL

Session Chairs: Nitin Jain, MD & Danielle Brander, MD

01:45 PM – 02:00 PM  BTK or BCL2i or Both for Frontline CLL - Danielle Brander, MD

02:00 PM – 02:15 PM  Pirtobrutinib, CAR T, and others. How to incorporate it in practice? - Alexey Danilov, MD, PhD

02:15 PM – 02:30 PM  Richter transformation. What’s new? - Sameer Parikh, MD

02:30 PM – 03:15 PM  Q & A and Case-Based Discussion 


03:15 PM – 03:45 PM  Break & Exhibits


03:45 PM – 05:15 PM  Session 6 - Low-Grade Lymphomas

Session Chair: Sonali Smith, MD 

03:45 PM – 04:00 PM  Are bi-specifics really going to have a role in indolent lymphomas? - Vivek Patel, MD

04:00 PM – 04:15 PM  Sequencing of treatments in 2L+ setting for follicular lymphoma - Michael Byrne, MD

04:15 PM – 04:30 PM  Updates in treatment of mantle cell lymphoma - Krish Patel, MD

04:30 PM – 05:15 PM  Q & A and Case-Based Discussion 


05:15 PM – 06:15 PM  Raise a Toast for Women in Hematology

**This is a non-CME activity**


DAY 3 – Sunday, October 13, 2024

07:00 AM – 08:00 AM  Registration, Exhibits, & Socialize

07:00 AM – 08:15 AM  Abstract Session *This is a non-CME Activity* 

 

Abstract Committee Chair:

Alexey Danilov, MD, PhD

Abstract Committee:

Hetty Carraway, MD; Nitin Jain, MD; Jack Khouri, MD, FACP; Jayastu Senapati, MD; Abhay Singh, MD, MPH 


08:15 AM – 08:45 AM  (Keynote)


08:45 AM – 10:15 AM  Session 7 - CML/MPN

Session Chairs: Naveen Pemmaraju, MD & Olatoyosi Odenike, MD

08:45 AM – 09:00 AM  Incorporating novel JAKi and other therapies in MF management - Raajit Rampal, MD, PhD

09:00 AM – 09:15 AM  Unanswered questions in CML in 2024 - Fadi Haddad, MD

09:15 AM – 09:30 AM  Advanced MPN: Unanswered questions - Anand Patel, MD

09:30 AM – 10:15 AM  Q & A and Case-Based Discussion - Ashwin Kishtagari, MD; Srinivas Tantravahi, MBBS, MRCP


10:15 AM – 11:00 AM  Break & Exhibits


11:00 AM – 01:00 PM  Session 8 - Multiple Myeloma - R/R

Session Chair: Melissa Alsina, MD

11:00 AM – 11:15 AM  Management of early relapses in myeloma-choosing the right combination - Melissa Alsina, MD

11:15 AM – 12:00 PM  Integrating immunotherapies into the treatment of relapsed MM – CART, ADC, and bispecifics - Krina Patel, MD, MSc

12:00 PM – 12:15 PM  Non-immune approaches for advanced myeloma - Gurbakhash Kaur, MD

12:15 PM – 01:00 PM  Q & A and Case-Based Discussion - Minoo Battiwalla, MD; Shaji Kumar, MD


01:00 PM  Adjourn

Hutton Hotel
1808 West End Ave,
Nashville, TN 37203
United States

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Conference Chair(s)

Shaji Kumar, MD

has a financial relationship (Grant Or Contract) with Research funding for clinical trials to the institution: Abbvie, Amgen, BMS, Carsgen,  Janssen,  ,  Astra-Zeneca, Novartis, Roche-Genentech,  Takeda, Tenebio, Molecular Templates;.
has a financial relationship (Professional Services) with Consulting/Advisory Board participation: (with no personal payments) Abbvie, Amgen, BMS, Janssen,  Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secure Biotherapeutics and (with personal payment) Oncopeptides, Beigene, Antengene ;.

Navneet Majhail, MD, MS, FASTCT

has a financial relationship (Independent contractor) with Anthem Inc;.
has a financial relationship (Independent contractor) with Incyte;.
Session Chair(s)

Sairah Ahmed, MD

has a financial relationship (Professional Services) with ADCT;.
has a financial relationship (Professional Services) with Tessa ;.
has a financial relationship (Professional Services) with myeloid;.
has a financial relationship (Professional Services) with Chimagen;.

Nisha Joseph, Associate Professor, MD

has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Grant Or Contract) with Beigene;.
has a financial relationship (Grant Or Contract) with Janssen Oncology;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Grant Or Contract) with GSK;.
has a financial relationship (Grant Or Contract) with Pfizer;.

Shaji Kumar, MD

has a financial relationship (Professional Services) with Consulting/Advisory Board participation: (with no personal payments) Abbvie, Amgen, BMS, Janssen,  Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secure Biotherapeutics and (with personal payment) Oncopeptides, Beigene, Antengene ;.
has a financial relationship (Grant Or Contract) with Research funding for clinical trials to the institution: Abbvie, Amgen, BMS, Carsgen,  Janssen,  ,  Astra-Zeneca, Novartis, Roche-Genentech,  Takeda, Tenebio, Molecular Templates;.

Naveen Pemmaraju

has no relevant financial relationships to disclose at this time.

Nirav Shah, MD

has a financial relationship (Independent contractor) with Miltenyi Biotec;.
has a financial relationship (Independent contractor) with BMS-Juno;.
has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Independent contractor) with Beigene;.
has a financial relationship (Independent contractor) with Lilly Oncology;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Epizyme;.
has a financial relationship (Independent contractor) with Cargo;.
has a financial relationship (Independent contractor) with Incyte;.
has a financial relationship (Independent contractor) with TG Therapeutics;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Tundra Therapeutics;.
has a financial relationship (Independent contractor) with Gilead-Kite;.
has a financial relationship (Independent contractor) with Seattle Genetics;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Independent contractor) with Galapagos;.
Speaker/Topic Presenter(s)

Sairah Ahmed, MD

has a financial relationship (Professional Services) with ADCT;.
has a financial relationship (Professional Services) with Tessa ;.
has a financial relationship (Professional Services) with myeloid;.
has a financial relationship (Professional Services) with Chimagen;.

Michael Byrne, DO

has no relevant financial relationships to disclose at this time.

Natalie Callander

has no relevant financial relationships to disclose at this time.

Alexey Danilov, MD, PhD

has a financial relationship (Independent contractor) with Beigene;.
has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Grant Or Contract) with MEI;.
has a financial relationship (Independent contractor) with Astra Zeneca;.
has a financial relationship (Independent contractor) with Lilly;.
has a financial relationship (Grant Or Contract) with Nurix;.

Bhagirathbhai Dholaria, MD

has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Wugen;.
has a financial relationship (Travel) with Janssen;.
has a financial relationship (Independent contractor) with MJH bio;.
has a financial relationship (Grant Or Contract) with Angiocrine;.
has a financial relationship (Grant Or Contract) with Gilead;.
has a financial relationship (Grant Or Contract) with MEI;.
has a financial relationship (Grant Or Contract) with Arivan;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Grant Or Contract) with Takeda;.
has a financial relationship (Grant Or Contract) with ADC therapeutics;.

Fadi Haddad

has no relevant financial relationships to disclose at this time.

Nisha Joseph, Associate Professor, MD

has a financial relationship (Grant Or Contract) with GSK;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Grant Or Contract) with Beigene;.
has a financial relationship (Grant Or Contract) with Janssen Oncology;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.

Prashant Kapoor, MD, FACP

has a financial relationship (Grant Or Contract) with Bristol Myers Squibb,;.
has a financial relationship (Grant Or Contract) with Sanofi;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Oncopeptides;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Grant Or Contract) with Karyopharm;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Grant Or Contract) with Regeneron;.
has a financial relationship (Grant Or Contract) with Ichnos;.
has a financial relationship (Grant Or Contract) with GlaxoSmithKline;.
has a financial relationship (Professional Services) with X4 Pharmaceuticals;.
has a financial relationship (Professional Services) with GlaxoSmithKline;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Grant Or Contract) with Loxo Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with AbbVie;.
has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with Angitia Bio;.

Marina Konopleva, MD, PhD

has a financial relationship (Professional Services) with Stemline Therapeutics;.
has a financial relationship (Professional Services) with F. Hoffmann-La Roche;.
has a financial relationship (Independent contractor) with Gilead;.
has a financial relationship (Grant Or Contract) with ImmunoGen;.
has a financial relationship (Independent contractor) with MEI Pharma;.
has a financial relationship (Independent contractor) with AbbVie;.
has a financial relationship (Grant Or Contract) with Rafael Pharmaceutical;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Grant Or Contract) with Sanofi Aventis;.
has a financial relationship (Independent contractor) with Boehringer;.
has a financial relationship (Grant Or Contract) with Stemline Therapeutics;.
has a financial relationship (Independent contractor) with F. Hoffmann-La Roche;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Immune Oncology;.
has a financial relationship (Independent contractor) with Legend Biotech;.
has a financial relationship (Grant Or Contract) with Precision Biosciences;.
has a financial relationship (Grant Or Contract) with Allogene;.
has a financial relationship (Independent contractor) with Sanofi Aventis;.
has a financial relationship (Professional Services) with Bakx Therapeutics;.
has a financial relationship (Professional Services) with Vincerx;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Grant Or Contract) with Janssen;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Independent contractor) with Redona;.
has a financial relationship (Professional Services) with Auxenion GmbH;.
has a financial relationship (Independent contractor) with Stemline Therapeutics;.
has a financial relationship (Professional Services) with Dark Blue Therapeutics;.
has a financial relationship (Independent contractor) with Vincerx;.
has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Grant Or Contract) with Gilead;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Grant Or Contract) with MEI Pharma;.
has a financial relationship (Grant Or Contract) with AbbVie;.
has a financial relationship (Intellectual Property Other) with Reata Pharmaceutical;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Independent contractor) with Sellas;.
has a financial relationship (Grant Or Contract) with Cellectis;.

Marlise Luskin, MD MSCE

has a financial relationship (Independent contractor) with KITE;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Grant Or Contract) with AbbVie;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Independent contractor) with Jazz;.

Anand Patel, Assistant Professor of Medicine; Medical Director, Inpatient Leukemia Service

has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Other) with Bristol Myers Squibb;.
has a financial relationship (Other) with AbbVie;.
has a financial relationship (Grant Or Contract) with Sumitumo;.
has a financial relationship (Grant Or Contract) with Kronos Bio;.

Krish Patel, MD

has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Caribou;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Professional Services) with Fate Therapeutics;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with Sana;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Epizyme;.
has a financial relationship (Professional Services) with Janssen/Pharmacyclics;.
has a financial relationship (Professional Services) with Xencor;.
Case Presenter(s)

Somedeb Ball, Assistant Professor of Medicine, Division of Hematology and Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN

has no relevant financial relationships to disclose at this time.

Jesus Berdeja

has a financial relationship (Grant Or Contract) with C4 Therapeutics;.
has a financial relationship (Grant Or Contract) with Fate Therapeutics;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Grant Or Contract) with Takeda;.
has a financial relationship (Professional Services) with Celgene;.
has a financial relationship (Professional Services) with Legend Biotech;.
has a financial relationship (Grant Or Contract) with Abbvie;.
has a financial relationship (Grant Or Contract) with Celularity;.
has a financial relationship (Grant Or Contract) with Ichnos Sciences;.
has a financial relationship (Grant Or Contract) with Sanofi;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Kite Pharma;.
has a financial relationship (Grant Or Contract) with 2Seventy Bio;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Grant Or Contract) with Cartesian Therapeutics;.
has a financial relationship (Grant Or Contract) with GSK;.
has a financial relationship (Grant Or Contract) with Karyopharm;.
has a financial relationship (Professional Services) with Bluebird;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Takeda;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Grant Or Contract) with CARsgen;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with Janssen;.
has a financial relationship (Grant Or Contract) with Zentalis;.
has a financial relationship (Professional Services) with CRISPR Therapeutics;.
has a financial relationship (Professional Services) with Roche;.
has a financial relationship (Grant Or Contract) with Acetylon;.

Naveen Pemmaraju

has no relevant financial relationships to disclose at this time.
Committee member(s)

Jack Khouri, MD

has a financial relationship (Professional Services) with Janssen;.

Available Credit

  • 13.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 13.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 13.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 13.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 13.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 13.50 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$450.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:

Link to register as an additional rep of a sponsoring company: https://education.binayfoundation.org/industry_registraiton_nocme .

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.